Ronald Wayne "Ron" Davis (born July 17, 1941) is professor of biochemistry and genetics, and director of the Stanford Genome Technology Center at Stanford University. Davis is a researcher in biotechnology and molecular genetics, particularly active in human and yeast genomics and the development of new technologies in genomics, with over 30 biotechnology patents. In 2013, it was said of Davis that "A substantial number of the major genetic advances of the past 20 years can be traced back to Davis in some way."

Scientific career

After completing his PhD at Caltech and a postdoctoral fellowship at Harvard University working with Jim Watson, Davis joined the faculty of Stanford's department of biochemistry in 1972. He became an associate professor in 1980, full professor in 1980, and joined the department of genetics as a professor in 1990. He became director of the Stanford Genome Technology Center in 1994. He was elected a member of the National Academy of Sciences in 1983.

Ronald W. Davis

Davis developed the R-loop technique of electron microscopy for mapping coding RNAs which led to the discovery of RNA splicing. With Janet E. Mertz, Davis was the first to demonstrate the use of restriction endonucleases for joining DNA fragments. Davis collaborated in the development of the first DNA microarray for gene expression profiling with Patrick O. Brown, and the gene expression profile of the first complete eukaryotic genome (Saccharomyces cerevisiae). Davis, with David Botstein, Mark Skolnick, and Ray White developed the method for constructing a genetic linkage map using restriction fragment length polymorphisms that enabled and led to the Human Genome Project.

Ronald W. Davis

He and his colleagues submitted a proposal to NIH to map the human genome in 1979; that proposal was turned down as being too ambitious. The Stanford Genome Technology Center was included in the Human Genome Project that began in 1990 and was completed in 2003.

Ronald W. Davis

In 2013, Davis founded the Stanford Chronic Fatigue Syndrome Research Center (now called ME/CFS Collaborative Research Center).

Recognition and awards

In 2013 Davis was named, alongside Elon Musk and Jeff Bezos, as one of today’s nine greatest innovators by The Atlantic: "A substantial number of the major genetic advances of the past 20 years can be traced back to Davis in some way."

He has won recognition for his contributions to genetic research from many groups, as early as 1976 and as recently as 2015, from one of his alumni colleges and from the National Academy of Sciences. Starting from his most recent award, here are awards and recognition Davis has received for his achievements in and contributions to science. In 2015, he received the Precision Medicine World Conference Luminary Award for his development of “R-loop Technique of Electron Microscopy”. In 2013, he received the Warren Alpert Foundation Prize.

He received the Gruber Prize in Genetics in 2011, which noted among other achievements, two landmark papers, one in 1977 concerning genome editing and another in 1980 which "helped launch the field of genomics." In 2007, California Institute of Technology gave him its Distinguished Alumni Award. In 2005, Davis received the Dickson Prize in Medicine. In 2004, he received the Lifetime Achievement Award from the Genetics Society of America. The National Academy of Sciences (NAS) gave him the 1982 NAS Award in Molecular Biology. In 1976, he received the Eli Lilly Award in Microbiology and Immunology.

Open Medicine Foundation

Dr. Davis is the director of the Scientific Advisory Board at the Open Medicine Foundation, a non-profit 501(c)(3) organization (EIN# 26-4712664), whose goal is to fund and initiate research into chronic complex diseases. Presently the foundation is invested in The End ME/CFS Project, which aims to fast-track research for a cure for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS).

In April 2019, a notable result was reported; a test of blood without red cells (white cells in plasma), identified ME/CFS patients from healthy people with 100% accuracy in a small sample, 20 patients and 20 healthy people. The test used a biotechnological device designed by Davis and his team, which is called the "nanoneedle".